Feasibility of a Flash Glucose Sensor Enabled Virtual Lifestyle Management Group in Patients With Type 2 Diabetes (T2DM): The STAND Study

2021 ◽  
Vol 45 (7) ◽  
pp. S26
Author(s):  
Sonja Reichert ◽  
Madison Hiemstra ◽  
Elisabeth Harvey ◽  
Amanda Mikalachki ◽  
Marc Mitchell
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Sensor ◽  
Lifestyle Management ◽  
Management Group

scholarly journals Not a Painless Condition: Rheumatological and Musculoskeletal Symptoms in Type 2 Diabetes, and the Implications for Exercise Participation

2020 ◽  
Vol 16 (3) ◽  
pp. 211-219
Author(s):  
Emily R. Cox ◽  
Jeff S. Coombes ◽  
Shelley E. Keating ◽  
Nicola W. Burton ◽  
Brooke K. Coombes
Keyword(s):  
Type 2 Diabetes ◽  
Management Strategy ◽  
Musculoskeletal Symptoms ◽  
Future Research ◽  
Community Settings ◽  
Lifestyle Management ◽  
Exercise Participation ◽  
Potential Impact ◽  
The Impact

Objectives:People with type 2 diabetes (T2D) are more likely to develop a range of rheumatological and musculoskeletal symptoms (RMS), and experience both chronic and widespread pain, compared with the general population. However, these symptoms are not commonly acknowledged by researchers, which hampers our understanding of the impact on this population. Since exercise is a key lifestyle management strategy for T2D and participation levels are typically low, understanding the potential impact of RMS on exercise participation is critical. The aim of this review is to summarise the literature regarding the prevalence and pathophysiology of RMS in T2D, the evidence for the benefits and risks associated with exercise on RMS, and the currently available tools for the reporting of RMS in both research studies and community settings.Methods:A narrative review.Results:There are numerous exercise trials in T2D, but few have sufficiently reported pain-related adverse events and even fewer have investigated the effects of exercise on RMS and chronic pain.Discussion:Recommendations for future research are provided.

scholarly journals Assessment of a Clinical Case for A Female Patient with Type 2 Diabetes Using the 2021 Consensus Report on Type 2 Diabetes Remission Discussions Sponsored by American Diabetes Association Based on GH-Method: math-physical medicine (No. 506)

2021 ◽  
Vol 6 (6) ◽  
Keyword(s):  
Type 2 Diabetes ◽  
Female Patient ◽  
Hba1c Level ◽  
Clinical Case ◽  
American Diabetes Association ◽  
Management Program ◽  
Lifestyle Management ◽  
One Year ◽  
Consensus Report

This 73-year-old female patient has suffered from type 2 diabetes (T2D), hypertension, and hyperlipidemua for over 20 years. She started taking Metformin in 1999 and ceased taking it on 1/7/2019. As of 4/3/2019, her HbA1C level was at 6.6%. Since 4/4/2019, she implemented a lifestyle management program which not only focuses on diet and exercise but also factors in sleep, stress, life routines and habits, as well as environmental factors. In this article, the author applies the final conclusions from the American Diabetes Association (ADA) 2021 consensus report regarding “T2D Remission”. For this clinical case, he analyzes the patient’s present conditions to determine if she satisfies the criteria of “T2D remission” or not. The defined criteria of “remission” include timespan of at least one year, HbA1C level less than 6.5%, fasting plasma glucose (FPG) level less than 126 mg/dL, and estimated HbA1C (eA1C) values based on the mean continuous glucose monitoring (CGM) glucose data less than 6.5%. In conclusion, according to the ADA 2021 consensus report, this female patient is in “remission” for T2D. In summary, over the past year from 9/5/2020 to 9/5/2021, her average lab-A1C is 6.3%, mean CGM FPG value is 102 mg/dL, and CGM eAG is 5.7%. First, the selected one year satisfies the timespan requirement cited in the 2021 consensus report. Her set of glucose data has been collected over ~3 years, after post-Metformin (started on 1/7/2019) and her initiation of lifestyle management program that began on 4/4/2019. Second, all of her A1C values, both lab-tested and CGM eA1C, are less than 6.5% and her mean CGM FPG level is less than 126 mg/dL. Finally, she keeps a regular routine with quarterly medical examinations to monitor various diabetes complications, including macrovascular, micro- vascular, neural, and hormonal systems. The author understands and agrees with the consensus report that diabetes is non-curable and at most is “controllable” or “partially reversible”. Nevertheless, this female patient has also adopted a similar lifestyle improvement program as the author in order to deal with the root causes of her multiple metabolic disorders, particularly T2D, instead of suppressing the external symptoms of diabetes through medication intervention.

scholarly journals Monogenic Diabetes in the Young, Pharmacogenetics and Relevance to Multifactorial Forms of Type 2 Diabetes

2008 ◽  
Vol 29 (3) ◽  
pp. 254-264 ◽  
Author(s):  
Martine Vaxillaire ◽  
Philippe Froguel
Keyword(s):  
Type 2 Diabetes ◽  
Glucose Sensor ◽  
Cell Function ◽  
Association Studies ◽  
Genome Wide Association Studies ◽  
Dominant Form ◽  
Genes Encoding ◽  
Autosomal Dominant Form ◽  
Β Cell Function

Abstract Most valuable breakthroughs in the genetics of type 2 diabetes for the past two decades have arisen from candidate gene studies and familial linkage analysis of maturity-onset diabetes of the young (MODY), an autosomal dominant form of diabetes typically occurring before 25 years of age caused by primary insulin secretion defects. Despite its low prevalence, MODY is not a single entity but presents genetic, metabolic and clinical heterogeneity. MODY can result from mutations in at least six different genes encoding the glucose sensor enzyme glucokinase and transcription factors that participate in a regulatory network essential for adult β-cell function. Additional genes have been described in other discrete phenotypes or syndromic forms of diabetes. Whereas common variants in the MODY genes contribute very modestly to type 2 diabetes susceptibility in adults, major findings emerging from the advent of genome-wide association studies will deliver an increasing number of genes and new pathways for the pathological events of the disease.

Lifestyle management in type 2 diabetes

2019 ◽  
Vol 12 (6) ◽  
pp. 310-314
Author(s):  
Major David Hindmarsh ◽  
Major Alex Nicholls
Keyword(s):  
Type 2 Diabetes ◽  
Body Composition ◽  
Lifestyle Management

Lifestyle management is a key component of care when managing patients with type 2 diabetes (T2D). With appropriate alteration to lifestyle it is possible to significantly improve T2D and achieve remission. This article aims to give an overview of the evidence and recommendations on body composition, diet, smoking, alcohol and exercise. It will also cover consultation techniques and resources available to improve care.

scholarly journals Requirements of an Application to Monitor Diet, Physical Activity and Glucose Values in Patients with Type 2 Diabetes: The Diameter

Nutrients ◽  
2019 ◽  
Vol 11 (2) ◽  
pp. 409 ◽  
Author(s):  
Niala den Braber ◽  
Miriam Vollenbroek-Hutten ◽  
Milou Oosterwijk ◽  
Christina Gant ◽  
Ilse Hagedoorn ◽  
...  
Keyword(s):  
Physical Activity ◽  
Type 2 Diabetes ◽  
Diabetes Management ◽  
Medication Use ◽  
Traditional Treatment ◽  
Pilot Studies ◽  
Lifestyle Management ◽  
Lifestyle Recommendations ◽  
Diabetes Mellitus Management

Adherence to a healthy diet and regular physical activity are two important factors in sufficient type 2 diabetes mellitus management. It is recognized that the traditional treatment of outpatients does not meet the requirements for sufficient lifestyle management. It is hypothesised that a personalized diabetes management mHealth application can help. Such an application ideally measures food intake, physical activity, glucose values, and medication use, and then integrates this to provide patients and healthcare professionals insight in these factors, as well as the effect of lifestyle on glucose values in daily life. The lifestyle data can be used to give tailored coaching to improve adherence to lifestyle recommendations and medication use. This study describes the requirements for such an application: the Diameter. An iterative mixed method design approach is used that consists of a cohort study, pilot studies, literature search, and expert meetings. The requirements are defined according to the Function and events, Interactions and usability, Content and structure and Style and aesthetics (FICS) framework. This resulted in 81 requirements for the dietary (n = 37), activity and sedentary (n = 15), glycaemic (n = 12), and general (n = 17) parts. Although many applications are currently available, many of these requirements are not implemented. This stresses the need for the Diameter as a new personalized diabetes application.

Sign in / Sign up

Export Citation Format

Share Document